BUSINESS AREA
Labtech
The Labtech business area provides products, solutions and services in fields such as diagnostics, biomedical research and laboratory analysis. The business area consists of two business units: Biomedical and Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies in Europe.
| Q2 | Q2 | ∆ | Jan-Jun | Jan-Jun | ∆ | Jul 2025- | Full year | |
| SEKm | 2026 | 2025 | % | 2026 | 2025 | % | Jun 2026 | 2025 |
| Net sales | 1,057 | 985 | 7 | 2,042 | 1,974 | 3 | 4,021 | 3,953 |
| Organic growth, % | 3 | 6 | 2 | 9 | 5 | |||
| EBITA | 142 | 122 | 16 | 271 | 242 | 12 | 524 | 495 |
| EBITA margin, % | 13.4 | 12.4 | 13.3 | 12.2 | 13.0 | 12.5 |
Net sales in Labtech by percent to million (). Organic growth amounted to percent and acquired growth to percent. Exchange rate effects had a marginal positive impact on net sales during the quarter.
EBITA by percent to SEK million (), corresponding to an EBITA margin of percent (). Exchange rate effects had a impact of SEK million on EBITA, corresponding to percent.
Labtech’s net sales by percent to SEK million (). Adjusted for exchange rate changes, net sales increased by 5 percent, of which organic growth increased by percent and acquired growth amounted to percent. Exchange rate changes had a impact on net sales of SEK million, corresponding to percent.
EBITA by percent to SEK million (), corresponding to an EBITA margin of percent (). Exchange rate changes had a impact on EBITA of SEK million, corresponding to percent.
Development in Labtech was strong during the quarter. Sales increased both organically and through acquisitions, while margins improved significantly. Previously won tenders continued to contribute positively, and several important new tenders were secured during the period.
The improvement efforts under way in several companies are yielding clear results in the form of higher margins and increased growth. This work is continuing with unchanged intensity.
Recently completed acquisitions made a clear contribution to the positive development in both sales and earnings.
The positive demand trend in the research segment identified in previous quarters continued and strengthened further.
Demand for diagnostic solutions that enable early and accurate test results, as well as more efficient processes, is increasing in both clinical operations and industry.
Investments in research and diagnostics are being made in several Eastern European countries, including Poland, Hungary, Romania and the Czech Republic, contributing to increased sales for several AddLife companies.